Prime Medicine (NYSEARCA:PRME) Trading Up 2.1%
Prime Medicine (NYSEARCA:PRME) Trading Up 2.1%
Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price was up 2.1% during mid-day trading on Thursday . The company traded as high as $18.61 and last traded at $18.61. Approximately 15 shares traded hands during trading, a decline of 100% from the average daily volume of 540,992 shares. The stock had previously closed at $18.22.
Prime Medicine,Inc.(NYSEArca:PRME-GET Rating)股價週四午盤上漲2.1%,最高報18.61美元,尾盤報18.61美元。交易中約有15股股票易手,較日均成交量540,992股下跌100%。該股此前收盤報18.22美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
A number of research analysts have recently issued reports on PRME shares. Jefferies Financial Group began coverage on Prime Medicine in a research note on Monday. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Prime Medicine in a report on Monday. They set a "neutral" rating and a $22.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a report on Monday. They set an "overweight" rating and a $27.00 target price for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a report on Monday. They set an "equal weight" rating and a $23.00 target price for the company.
一些研究分析師最近發佈了關於PRME股票的報告。傑富瑞金融集團(Jefferies Financial Group)週一在一份研究報告中開始報道Prime Medicine。他們為該股設定了“買入”評級和25.00美元的目標價。高盛在週一的一份報告中開始報道春華醫藥的股票。他們為該公司設定了“中性”評級和22.00美元的目標價。摩根大通(JPMorgan Chase&Co.)週一在一份報告中開始報道Prime Medicine的股票。他們為該公司設定了“增持”評級和27美元的目標價。最後,摩根士丹利在週一的一份報告中開始對春華醫藥的股票進行報道。他們為該公司設定了“同等權重”的評級和23.00美元的目標價。
Prime Medicine Trading Up 3.8 %
Prime Medicine股價上漲3.8%
The company's fifty day moving average price is $19.55 and its 200-day moving average price is $19.99.
該公司的50日移動均線價格為19.55美元,200日移動均線價格為19.99美元。
Insider Transactions at Prime Medicine
Prime Medicine的內幕交易
Prime Medicine Company Profile
優質醫藥公司簡介
(Get Rating)
(獲取評級)
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Prime Medicine,Inc.是一家生物技術公司,通過部署基因編輯技術提供基因療法來治療疾病。它為Prime Edants提供了Prime Editor蛋白質和pegRNA,前者包括CaS蛋白質和逆轉錄酶之間的融合;後者將Prime Editing定位於特定的基因組位置,並提供對目標DNA序列進行所需編輯的模板。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- NVIDIA's Rally Picks Up Pace Into Year End
- Nothing Micro About Super Micro Computer's Price & Earnings Gains
- Why Are Bears Still Going Short on AGNC Investment?
- 免費獲取StockNews.com關於Prime Medicine(PRME)的研究報告
- BJ‘s批發俱樂部:當心賣方
- 馬倫汽車股票的下一個催化劑是12月23日
- NVIDIA的拉力賽加快了年底的步伐
- 超微計算機的價格和收益收益並不是微不足道的
- 為什麼貝爾斯登仍在做空AGNC投資公司?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
接受《頂級醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Prime Medicine和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。